APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon-like Peptide-2 (GLP-2) Agonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Glucagon-like Peptide-2 (GLP-2) Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026179 pages

Choose your research edition.

Industry ResearchGlucagon-like Peptide-2 (GLP-2) Agonist Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist include Takeda Pharmaceuticals. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Glucagon-like Peptide-2 (GLP-2) Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glucagon-like Peptide-2 (GLP-2) Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glucagon-like Peptide-2 (GLP-2) Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glucagon-like Peptide-2 (GLP-2) Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Company

Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type

Gattex

Revestive

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application

Hospital

Pharmacy

Other

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon-like Peptide-2 (GLP-2) Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon-like Peptide-2 (GLP-2) Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon-like Peptide-2 (GLP-2) Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Glucagon-like Peptide-2 (GLP-2) Agonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends Table 2. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers Table 3. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges Table 4. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers, Product Type & Application Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Gattex Table 17. Major Manufacturers of Revestive Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2026) Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2027-2032) Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (K Units) Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (K Units) Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2026) Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2026) Table 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2027-2032) Table 36. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (K Units) Table 38. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (K Units) Table 39. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2026) Table 40. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2027-2032) Table 41. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026) & (K Units) Table 43. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2021-2026) Table 44. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 48. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 49. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 51. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2021-2026) Table 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2027-2032) Table 63. Takeda Pharmaceuticals Company Information Table 64. Takeda Pharmaceuticals Business Overview Table 65. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio Table 67. Takeda Pharmaceuticals Recent Development Table 68. Key Raw Materials Table 69. Raw Materials Key Suppliers Table 70. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List Table 71. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Product Image Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2032) & (K Units) Figure 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Gattex Image Figure 9. Revestive Image Figure 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2032) Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2032) Figure 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2032) Figure 25. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 27. U.S. Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 32. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 39. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 47. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Figure 58. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Figure 60. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Gattex
  • Revestive
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Dynamics
  1. 2.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
  2. 2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers
  3. 2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges
  4. 2.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints
3 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Manufacturers
  1. 3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers, Product Type & Application
  7. 3.7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Glucagon-like Peptide-2 (GLP-2) Agonist Tier 1, Tier 2, and Tier 3
4 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Type
  1. 4.1 Glucagon-like Peptide-2 (GLP-2) Agonist Type Introduction
  2. 4.1.1 Gattex
  3. 4.1.2 Revestive
  4. 4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
  5. 4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  7. 4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2032)
  8. 4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type
  9. 4.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  11. 4.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2032)
5 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Application
  1. 5.1 Glucagon-like Peptide-2 (GLP-2) Agonist Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
  6. 5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  8. 5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2032)
  9. 5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application
  10. 5.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  12. 5.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2032)
6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region
  1. 6.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026)
  4. 6.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region
  1. 7.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region
  2. 7.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2021-2026)
  4. 7.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2027-2032)
  5. 7.1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032)
  8. 7.2.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032)
  11. 7.3.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Analysis
  2. 9.1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process
  6. 9.2 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
  9. 9.2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst